The Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) voted in favor for the use of Shingrix (zoster vaccine recombinant, adjuvanted; GlaxoSmithKline) for the prevention of shingles (herpes zoster).
The ACIP recommends Shingrix for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years and adults who previously received Zostavax (zoster vaccine live; Merck). The Committee voted that Shingrix is preferred over Zostavax for the prevention of zoster and related complications.
“Today’s vote is an important step forward for the prevention of shingles, as the expanded recommendation will bring access to a vaccine with efficacy of greater than 90%, which will help protect more American adults from a painful and serious condition,” stated Dr. Thomas Breuer, SVP and CMO of GSK Vaccines.
Shingrix was approved earlier this month by the Food and Drug Administration (FDA) for use in adults aged ≥50 years. It combines glycoprotein E, an antigen, with AS01B, an adjuvant system intended to induce a strong and sustained immune response to overcome the age-related decline in immunity. Phase 3 clinical data supporting the approval indicated vaccine efficacy of >90% against shingles across all age groups, as well as sustained efficacy over a 4-year follow-up.
The ACIP’s recommendations will be passed to the director of the CDC and U.S. Department of Health and Human Services for approval. The final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR).
For more information call (888) 825-5249 or visit Shingrix.com.